BioTuesdays

Category - Markets

DURECT
Markets

HCW assumes coverage of DURECT at buy

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28. “Our focus is on the novel epigenetic regulator...

February 28, 2017
Cempra
Markets

Roth upgrades Cempra to buy

Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The...

February 27, 2017
Zynerba Pharmaceuticals Logo
Markets

Maxim starts Zynerba Pharma at buy

Maxim Group initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and 12-month price target of $32. The stock closed at $22.10 on Feb. 23. Analyst Lauren Chung writes that 2017 could be a...

February 24, 2017
Reata Pharma
Markets

Stifel starts Reata Pharma at buy

Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22. “Our positive thesis centers on what we see as blockbuster potential for...

February 23, 2017
ANI Pharmaceuticals
Markets

Roth downgrades ANI Pharma to neutral

Roth Capital Partners downgraded ANI Pharmaceuticals (NASDAQ:ANIP) to “neutral” from “buy,” pending the company’s 2017 financial guidance. Roth maintained its $69 price target for the stock, which was quoted at $59.53...

February 22, 2017
Argos Therapeutics
Markets

Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase...

February 22, 2017
Entellus Medical
Markets

BTIG downgrades Entellus Medical to neutral

BTIG downgraded Entellus Medical (NASDAQ:ENTL) to “neutral” from “buy,” saying that “something has gone off course” after the company reported Q4 results on Feb. 21. The stock closed at $17.08 yesterday. “For some time...

February 22, 2017
AnaptysBio
Markets

Stifel starts AnaptysBio at buy

Stifel launched coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and $30 price target. The stock closed at $23.89 on Feb. 17. “AnaptysBio, at its core, is a unique antibody generation company capable of directed...

February 21, 2017
ObsEva Logo
Markets

Leerink starts ObsEva at OP

Leerink initiated coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and a 12-month price target of $21. The stock closed at $13.21 on Feb. 17. ObsEva is a clinical-stage biopharmaceutical company focused...

February 21, 2017
Medicure
Markets

Mackie ups Medicure price target to $14.70

Mackie Research Capital raised its price target for Medicure (TSX-V:MPH) to $14.70 from $6.90, reflecting the recent acquisition of a majority interest in Apicore as well as a change in the trend of Aggrastat...

February 17, 2017